Xilia 1 Tablet contains Glimepiride 1 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Glimepiride acts by stimulating insulin secretion from the pancreatic beta cells, thereby reducing blood glucose levels. It is typically prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled by lifestyle modifications alone. The medication is effective in lowering both fasting and postprandial blood glucose concentrations. Xilia 1 Tablet should be administered once daily with breakfast or the first main meal to optimize absorption and minimize the risk of hypoglycemia. Dose adjustments may be necessary based on individual patient response and glycemic targets. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in elderly patients due to an increased risk of hypoglycemia. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Xilia 1 Tablet is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas.